

AP05292CP-N**SET / I2PP2A Control Peptide****Alternate names:**

I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I

Quantity:

50 µg

Concentration:

1.0 mg/ml

Background:

Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression are found in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.

Uniprot ID:

[H0UJ37](#)

NCBI:

[NP_001116293.1](#)

GeneID:

[100130890](#)

Format:

State: Liquid peptide

Buffer System: PBS with 0.08% sodium azide

Applications:

Western blot.

Incubate antibody neat with at least a 50 fold stoichiometric excess of blocking peptide at 37°C for 20 minutes (molecular weights of peptide and antibody are ~2.5 kDa and ~160 kDa, respectively). Antibody can then be diluted to a concentration suitable for Western blot.

Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Specificity:

Control peptide for antibodies AP05292PU-N and AP05292SU-N only.

Storage:

Store at -20°C.

Avoid repeated freezing and thawing.

Shelf life: one year from despatch.